About this trial
Esophagectomy is most curative treatment to esophageal cancer. However, osteoporosis , which is characterized by both the loss of bone mass and the deterioration of bone architecture, is a serious complication in the long course after surgery. The aim of the present study was to evaluate osteoporosis by using high-resolution peripheral quantitative computed tomography (HR-pQCT) in the long course after esophagectomy. At least 3 years should have elapsed since operation without recurrence of esophageal cancer.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
At least 3 years have elapsed since esophagectomy due to esophageal cancer
Provide signed informed consent
Disqualifiers
Current use of the following osteoporosis agents; Teriparatide, Denosumab, and - -
bisphosphonate
Present malignancy (except in situ carcinoma)
Radiotherapy
Trial population
Japanese
Trial design
Cohort
Prospective
Treatments tested in this trial
esophagectomy
Procedure/Surgeryesophagectomy
Treatment groups
Trial outcomes
Primary outcomes
Comparing bone microstructure in control and Esophagectomy groups
volumetric bone mineral density
Secondary outcomes
Comparing bone microstructure with serum biomarkers of osteoporosis
Correlation between bone mineral density in esophagectomy and biomarkers (25-hydroxyvitaminD, calcium, iPTH, P1NP, ICTP, TRACP5b)
Comparing bone microstructure with dual-energy X-ray absorptiometry
Correlation of bone mineral density between esophagectomy and DXA
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: